Viking Therapeutics (VKTX) Share-based Compensation (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Share-based Compensation data on file, last reported at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 196.75% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (up 6091.99% YoY), and the FY2025 full-year result was $18.3 million, up 8100.9% from the prior year.
• Share-based Compensation rose to $33.7 million in Q1 2026, from -$1.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $33.7 million in Q1 2026 to a low of -$23.8 million in Q4 2024.
• A 5-year average of $4.2 million and a median of $2.9 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 547.23% in 2022 and tumbled 12771.28% in 2024, its largest moves.
• Tracing VKTX's Share-based Compensation over 5 years: stood at -$1.4 million in 2022, then surged by 112.97% to $188000.0 in 2023, then plunged by 12771.28% to -$23.8 million in 2024, then surged by 94.39% to -$1.3 million in 2025, then jumped by 2620.58% to $33.7 million in 2026.
• Business Quant data shows VKTX's Share-based Compensation at $33.7 million in Q1 2026, -$1.3 million in Q4 2025, and $7.3 million in Q3 2025.